309 related articles for article (PubMed ID: 31472914)
1. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
Sadeghi S; Bejjani A; Finn RS
Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
3. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
4. Milestones in the pathogenesis and management of primary liver cancer.
Nault JC; Cheng AL; Sangro B; Llovet JM
J Hepatol; 2020 Feb; 72(2):209-214. PubMed ID: 31954486
[No Abstract] [Full Text] [Related]
5. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
Parks AL; McWhirter RM; Evason K; Kelley RK
J Gastrointest Cancer; 2015 Jun; 46(2):161-5. PubMed ID: 25662892
[No Abstract] [Full Text] [Related]
6. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
7. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
8. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for cholangiocarcinoma: a 2021 update.
Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
11. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
Stefanini B; Tonnini M; Marseglia M; Tovoli F
Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
[No Abstract] [Full Text] [Related]
12. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
13. [Systemic treatment of liver and biliary tumors].
Malek NP; Greten T; Kubicka S
Internist (Berl); 2007 Jan; 48(1):46-9. PubMed ID: 17177032
[TBL] [Abstract][Full Text] [Related]
14. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
15. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
Sipra QUAR; Shroff R
Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
[No Abstract] [Full Text] [Related]
16. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
17. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
18. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
Marin JJ; Macias RI
Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
[No Abstract] [Full Text] [Related]
19. Biomarkers for Hepatobiliary Cancers.
Nault JC; Villanueva A
Hepatology; 2021 Jan; 73 Suppl 1():115-127. PubMed ID: 32045030
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
Marks EI; Yee NS
World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
